These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9141056)

  • 1. Effect of tolcapone on plasma and striatal apomorphine disposition in rats.
    Coudoré F; Durif F; Duroux E; Eschalier A; Fialip J
    Neuroreport; 1997 Mar; 8(4):877-80. PubMed ID: 9141056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake.
    Budygin EA; Gainetdinov RR; Kilpatrick MR; Rayevsky KS; Männistö PT; Wightman RM
    Eur J Pharmacol; 1999 Apr; 370(2):125-31. PubMed ID: 10323260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy.
    Jorga KM; Fotteler B; Heizmann P; Zürcher G
    Eur J Clin Pharmacol; 1998 Jul; 54(5):443-7. PubMed ID: 9754991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
    J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.
    Jorga KM
    Neurology; 1998 May; 50(5 Suppl 5):S31-8. PubMed ID: 9591520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The disposition of the tolcapone 3-O-methylated metabolite is affected by the route of administration in rats.
    Funaki T; Onodera H; Ushiyama N; Tsukamoto Y; Tagami C; Fukazawa H; Kuruma I
    J Pharm Pharmacol; 1994 Jul; 46(7):571-4. PubMed ID: 7996385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Microdialysis study of tolcapone effect during blockage of neuronal dopamine reuptake caused by GBR-12909].
    Budygin EA; Gaĭnetdinov RR; Raevskiĭ KS; Li IH; Mannisto PT
    Eksp Klin Farmakol; 1997; 60(5):8-10. PubMed ID: 9483396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
    Jorga KM; Sedek G; Fotteler B; Zürcher G; Nielsen T; Aitken JW
    Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
    Jorga K; Banken L; Fotteler B; Snell P; Steimer JL
    Clin Pharmacol Ther; 2000 Jun; 67(6):610-20. PubMed ID: 10872643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
    Gasser UE; Jorga K; Crevoisier C; Hovens SE; van Giersbergen PL
    Eur Neurol; 1999; 41(4):206-11. PubMed ID: 10343151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of subchronic administration of tolcapone on release of striatum dopamine and its metabolites induced by L-DOPA and carbidopa].
    Budygin EA; Gaĭnetdinov RR; Raevskiĭ KS; Mannisto PT
    Biull Eksp Biol Med; 1998 Feb; 125(2):168-71. PubMed ID: 9559129
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
    Tohgi H; Abe T; Yamazaki K; Saheki M; Takahashi S; Tsukamoto Y
    Neurosci Lett; 1995 Jun; 192(3):165-8. PubMed ID: 7566641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of an effect of Madopar on the disposition of tolcapone and its 3-O-methylated metabolite in rats.
    Funaki T; Onodera H; Ushiyama N; Tsukamoto Y; Tagami C; Fukazawa H; Kuruma I
    J Pharm Pharmacol; 1995 Jun; 47(6):539-42. PubMed ID: 7674141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase.
    Törnwall M; Tuomainen P; Männistö PT
    Eur J Pharmacol; 1993 Aug; 239(1-3):39-45. PubMed ID: 8223912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites.
    Jorga KM; Kroodsma JM; Fotteler B; Heizmann P; Meyer J; Rasch MC; van Hattum J
    Clin Pharmacol Ther; 1998 Jun; 63(6):646-54. PubMed ID: 9663179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats.
    Brannan T; Martínez-Tica J; Yahr MD
    Neurology; 1992 Mar; 42(3 Pt 1):683-5. PubMed ID: 1549240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of COMT inhibition on levodopa pharmacology and therapy.
    Goetz CG
    Neurology; 1998 May; 50(5 Suppl 5):S26-30. PubMed ID: 9591519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.